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Abstract
Objectives—The brain blood vessels of patients with type-2 diabetes and dementia have 
deposition of amylin, an amyloidogenic hormone co-secreted with insulin. It is not known whether 
vascular amylin deposition is a consequence or a trigger of vascular injury. We tested the 
hypothesis that the vascular amylin deposits cause endothelial dysfunction and microvascular 
injury and are modulated by the amylin transport in the brain via plasma apolipoproteins.
Methods—Rats overexpressing amyloidogenic (human) amylin in the pancreas (HIP rats) and 
amylin knockout (AKO) rats intravenously infused with aggregated amylin were used for in vivo 
phenotyping. We also carried out biochemical analyses of human brain tissues and studied the 
effects of the aggregated amylin on endothelial cells, ex vivo.
Results—Amylin deposition in brain blood vessels is associated with vessel wall disruption and 
abnormal surrounding neuropil in patients with type-2 diabetes and dementia, in HIP rats, and in 
AKO rats infused with aggregated amylin. HIP rats have brain microhemorrhages, white matter 
injury and neurologic deficits. Vascular amylin deposition provokes loss of endothelial cell 
coverage and tight junctions. Intravenous infusion in AKO rats of human amylin, or combined 
human amylin and apolipoprotein E4, showed that amylin binds to plasma apolipoproteins. The 
intravenous infusion of apolipoprotein E4 exacerbated the brain accumulation of aggregated 
amylin and vascular pathology in HIP rats.
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Interpretation—These data identify vascular amylin deposition as a trigger of brain endothelial 
dysfunction that is modulated by plasma apolipoproteins and represents a potential therapeutic 
target in diabetes-associated dementia and stroke.
Introduction
Microvascular-related brain injury is associated with focal neurologic deficits and 
dementia1–5. The distal territories of small penetrating vessels (arterioles and capillaries) 
supplying brain white matter are particularly vulnerable to vascular pathologies (also known 
as cerebral small vessel disease). High blood pressure, atherosclerosis and inflammation are 
among the major causes of brain white matter disease of vascular origin1–5. Recent 
investigations6–8 have revealed that the brain microvasculature of patients with dementia 
contains large deposits of amylin, a ~4 kDa peptide co-synthesized with insulin by 
pancreatic β-cells9. Vascular deposition of amylin is particularly abundant in the brains of 
patients with dementia and type-2 diabetes6,7. The peptide amylin (or islet amyloid 
polypeptide) normally crosses the blood brain barrier10 and binds to neurons in the feeding 
centers11,12, where it is believed to induce an anorexic effect13,14. In patients with type-2 
diabetes, amylin forms amyloid in the pancreatic islets that triggers β-cell apoptosis9,15,16. 
Deposits of aggregated amylin are also identified in failing hearts17,18 and kidneys19 of 
individuals with type-2 diabetes or obesity. Of note, apolipoprotein E4 (APOE4), which is 
strongly associated with β amyloid (Aβ) pathology20,21, modulates amylin aggregation22 
and amylin amyloid formation23,24.
Amylin from species that do not develop type-2 diabetes (i.e. mice and rats) is non-
amyloidogenic due to proline substitutions at the 25, 28, and 29 sites25. Pharmacological 
induction of insulin resistance in transgenic mice expressing the amyloidogenic amylin 
variant (i.e., human amylin) caused intra- and extracellular amylin amyloid deposition, β-
cell apoptosis and overt hyperglycemia26. Similar pathologic changes occur in rodents 
overexpressing human27, but not murine amylin16. We previously reported that rats 
overexpressing human amylin in the pancreas accumulate aggregated amylin in the brain28, 
which correlates with the development of neuroinflammation28,29, reduced synthesis (by 
>50%) of catecholamine precursors (phenylalanine and tyrosine)30 and neurologic deficits28. 
Furthermore, a recent study demonstrated that transgenic mice overexpressing human 
amylin in pancreatic islets and a mutant form of the amyloid precursor protein (APP) in 
neurons have exacerbated Aβ pathology compared to transgenic mice expressing only one or 
the other protein31.
Distinct from other diabetic complications, glucose dysregulation does not appear to be the 
primary determinant of progressive brain injury in patients with diabetes32–37. The 
pathophysiology underlying slowly progressive functional and structural brain changes in 
the setting of type-2 diabetes is largely unknown32–37. Given the toxicity of aggregated 
amylin9,15–19, we hypothesized that the complex pathophysiology32–37 underlying slowly 
progressive functional and structural brain changes in patients with type-2 diabetes involves 
accumulation of aggregated amylin in the brain blood vessels. Here, we tested the 
hypothesis that aggregated amylin circulates through the blood, deposits in brain blood 
vessels (possibly via the interaction with plasma apolipoproteins) and provokes brain 
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microvascular injury by degrading endothelial cell coverage and tight junctions. To test this 
hypothesis, we performed in vivo phenotyping of rats expressing amyloidogenic (human) 
amylin in the pancreas (HIP rats27) and generated amylin knockout (AKO) rats that were 
intravenously infused with aggregated human amylin. We also carried out biochemical 
analyses of brain tissues from humans and studied the effects of the aggregated amylin on 
endothelial cells, ex vivo. Our findings may contribute to the understanding of the complex 
molecular mechanisms underlying the diabetes-associated stroke and dementia32–37.
Methods
This investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) 
and was approved by the Institutional Animal Care and Use Committees at University of 
Kentucky.
Paraffin embedded brain tissues were provided by the Alzheimer’s Disease Center biobank 
at the University of Kentucky. The protocol was approved by the Institutional Review Board.
For immunohistochemistry, formalin fixed dorsolateral frontal cortex (Brodmann area 9) 
tissue was used from three autopsied individuals >80 years of age at death, with type-2 
diabetes and dementia and three age-matched cognitively normal individuals without type-2 
diabetes (Supplementary Table 1). The absence/presence of diabetes was determined during 
life (at longitudinal clinical visits) by patient or caregiver self-report and the use of diabetic 
medications38. The assessment of clinical dementia and the neuropathologic features - 
neuritic amyloid plaques (Consortium to Establish a Registry for Alzheimer’s Disease; 
CERAD), Braak NFT stage and cerebral amyloid angiopathy (CAA) severity - were scored 
as previously described39–43. Neuropathological information, APOE genotype, age and sex 
of each individual included in the present study are summarized with specific findings 
related to the vascular amylin pathology.
Experimental animals
HIP rats (n = 79; breeding pairs provided by Charles River Laboratory) were used in 
behavior testing and physiological analyses. HIP rats are Sprague-Dawley rats that 
overexpress (3-fold) human amylin in the pancreatic β-cells27. Wild-type (WT) littermate 
rats (n = 49) were used as non-diabetic controls.
AKO rats were used to identify a possible interaction of amylin with plasma apolipoproteins 
(APOE) and to test whether intravenous infusion of aggregated human amylin injures the 
brain microvessels independently of glucotoxicity. AKO rats (rather than WT rats) were 
used in amylin-injection experiments to eliminate the confound that rodent amylin and 
human amylin form mixed oligomers44. AKO rats were generated in collaboration with 
Transposagen Biopharmaceuticals (Lexington, KY). The rat amylin gene was targeted at two 
sites by producing double strand breaks in the genome using the CRISPR/CAS9 system45. 
The CRISPR gRNAs and Cas9 mRNA were microinjected into the pronucleus of fertilized 
Sprague-Dawley rat embryos by standard techniques and the embryos were reimplanted to 
produce the genetically modified offspring. Amylin gene knock-out was confirmed by 
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genotyping using the following primers for DNA amplification: Forward: 3′-
AGAGCTAAGCAAGTTGAGGGAT-5′, and Reverse: 
ACCACTAGTTCACATTCACAGAGG. AKO rat pancreas was tested for amylin 
immunoreactivity signal by Western blot.
Behavior testing
Inclined plane—Rats were placed on the flat plane in the horizontal position with head 
either facing up or down to the side to be raised. Starting at 30°, the angle was increased at 
2°/second. The angle at which the animal starts to free-fall was recorded. Each rats received 
3 trials per head facing direction. Rats were allowed to rest 1 minute between trials. Results 
were averaged for 6 trials.
Cylinder test/Forelimb use test—To evaluate forelimb deficits, the animal was placed 
in a transparent cylinder for 5 minutes, and the activity was videorecorded. The time that 
forepaws contacted with the cylinder wall during vertical rearing up was calculated using 
slow-motion playback software (Kinovea).
Morris Water Maze—Visuospatial learning and memory retention was tested in a 1.5 m 
diameter Morris Water Maze46. HIP and WT littermate rats with no motor impairments were 
given 10 learning trials per day for two consecutive days using random starting locations (N, 
E, S, W). Animals were allowed to stand on the platform for 30 s after the first trial and 15 s 
after each additional trial. If the animals failed to locate the platform, they were picked up 
and put on the platform for 15 s. To assess reference memory, a probe trial was given 24 
hours after the second acquisition day. The probe trial was scored on latency to cross the 
platform. Trials were recorded by EthoVision XT software (Noldus, VA).
Magnetic resonance imaging
MRI data were acquired using a horizontal 7T nuclear magnetic resonance scanner 
(ClinScan, Bruker BioSpin MRI, Ettlingen, Germany) and a 38-mm rat brain coil. Rats were 
first anesthetized with isoflurane (4.0% for induction, 1.2% for maintenance) and air 
mixture. Heart rate (90 to 130 b.p.m.), respiration rate, and rectal temperature (37±0.5°C) 
were continuously monitored. Heart rate and blood oxygen saturation level were maintained 
within normal physiological ranges. Coronal T2-weighted MR images were obtained using 
the following variables: repetition time (TR), 3000 ms; echo time (TE), 24 ms; field of view 
(FOV), 2.5 × 2.5 cm2; acquisition matrix 128 × 128; thickness, 1mm, 7 slices. Ventricular 
volume was measured from the frontal horn of lateral ventricle to the foramen of Luschka by 
combining hyper-intense ventricular area using ImageJ over all slices and multiplying by 
section thickness47. Similarly, total brain volume was measured by multiplying combined 
brain area over all slices to section thickness. Parenchymal volume was calculated by 
subtracting ventricular volume from total brain volume.
Isolation of rat brain capillaries
Freshly isolated brain was homogenized in capillary PBS (cPBS) (137 mM NaCl, 2.7 mM 
KCl, 8.1 mM Na2HPO4, 1.47 mM KH2PO4, 1.05 mM MgCl2, 0.9 mM CaCl2, 5 mM 
glucose, 0.9 mM sodium pyruvate). To separate blood vessels from brain parenchyma, the 
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brain homogenate was centrifuged in 30% Ficoll PM 400 solution (F-4375, Sigma, MO) at 
5000 xg for 20 minutes, 4°C. The capillaries were then isolated by the glass-bead column 
filtration method. In the first step, the pellet resulting from the centrifugation was re-
suspended with 1% BSA in cPBS and passed through a 300 μm strainer. Then, the filtered 
pellet suspension was added into the glass bead column. Two hundred ml 1% BSA was 
passed through the column. Capillaries were retrieved from the beads by agitation in 1% 
BSA and filtering through a strainer, followed by centrifugation at 500 xg for 5 minutes, 
4°C. Capillaries were washed twice with cPBS before the experiment. For quality control, 
capillaries were stained with Texas red dye and were examined under confocal microscope.
Cerebral blood flow measurement
Fluorescent microspheres (15 μm diameter; F8839, Thermo Fisher, MA) were vortexed for 
30 s in heparinized saline (106/mL fluorescent microspheres). Anesthetized HIP and WT rats 
were injected with a 200 μl volume containing microspheres and heparinized saline through 
the jugular line, twice (15 mins apart). Animals were sacrificed and the brains collected for 
tissue digestion, capillary isolation (as described above) and microsphere recovery by 
filtration followed by fluorescence measurements.
Equal weights of brain capillaries and remaining parenchymal tissue from WT and HIP rats 
were individually digested in 4M KOH and 2% tween 80 (Sigma Aldrich, MO). The tissue 
was completely digested within 24 hours. The digested tissue was then filtered through 
10μm pore polycarbonate filters (Millipore, CA). The vial and filtering syringe were washed 
twice with 2% tween, and wash was filtered to recover residual microspheres. The filter and 
filtered material from each tissue were placed in 1.25 ml of Cellosolve acetate (Sigma 
Aldrich, MO) in tubes. After ≥4 and up to 24 hours, 100μl samples from each tube were 
placed in a 96 well microplate and the florescence of each was determined by florescent 
spectrophotometer.
Histology
HIP, WT and AKO rat brains were analyzed by staining with Prussian blue and Luxol fast 
blue (LFB). For Prussian blue staining, sections were microwaved in solution containing 5% 
HCl and 5% potassium ferrocyanide (14459-95-1, Acros, Geel, Belgium). Nuclei were 
stained with neutral red (N7005, Sigma, MO). For Luxol fast blue staining, sections were 
treated with luxol fast blue (AC212170250, Acros, Geel, Belgium) solution O/N at 56°C, 
followed by 95% ethanol and dH2O rinse. Slides were differentiated in lithium carbonate 
solution then 70% ethanol, followed by H&E staining (BP2424-25, E511-100, Fisher, PA). 
Images were obtained on the Nikon Eclipse 55i upright microscope (Nikon).
Immunohistochemistry
We used brain tissues from humans, HIP, WT and AKO rats. Tissues were processed as 
previously described6,29. Antibodies against amylin (1:200, T-4157, Bachem-Peninsula 
Laboratories, CA), glial fibrillary acidic protein (GFAP; 1:600, MAB360, Millipore, MA) or 
myelin basic protein (MBP; 1:5,000, AMAB91064, clone CL2829, Sigma, MO) were the 
primary antibodies. Anti-mouse or anti-rabbit IgG (1:50, A3562, A3687, Sigma, MO) were 
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secondary antibodies. The specificity of the amylin antibody in both human and rat brain 
tissues was established in previous studies6,7,29.
Demyelination scoring
Demyelination of the white matter (MBP and LFB staining) was scored by a blinded 
observer. Ordinal pathologic scoring was used, ranging from normal to severe demyelination 
(0–3)48.
Immunofluorescence
We used brain tissues from humans, HIP, WT and AKO rats, and isolated brain capillaries 
from HIP, WT and AKO rats. Brain tissue was processed as previously29 described. Brain 
capillaries were isolated (as described above) and then plated on laminin (23017-015, Gibco, 
MA) coated chambered coverglass for 1-hour, to allow time to attach.
Antibodies against human amylin (1:200, SC-377530, Santa Cruz, TX), collagen IV (1:500, 
SAB4200500, Sigma, MO), caveolin1 (1:1,000, sc-894, Santa Cruz, TX) and APOE (1:200, 
ab183597, Abcam, MA) were the primary antibodies. Alexa Fluor 488 conjugated anti-
mouse IgG (A11029, Invitrogen, MA) and Alexa Fluor 568 conjugated anti-rabbit IgG 
(A11036, Invitrogen, MA) were the secondary antibodies.
Immunoprecipitation
HIP rat plasma was investigated in these experiments. Protein concentration was determined 
by BCA protein assay prior to immunoprecipitation. APOE was precipitated from 700 μg 
plasma protein. Samples were incubated at 4°C O/N with 5 μg anti-APOE antibody 
(ab183597, Abcam, MA) or anti-APOA-1 antibody (H00000335-D01P, Abnova). Antibody-
antigen complex was precipitated out by protein A/G agarose (20421, Thermo Scientific), 
rotated for 3 hours at 4°C. Immunoprecipitates were collected by centrifugation followed by 
washing three times with buffer (5 mM EGTA, 50 mM Tris, 1% Triton X-100, phosphatase 
and protease inhibitors 1:100 ratio, pH 7.5). Proteins were eluted two times with elution 
buffer (0.2 M Glycine, 80 mM HCl, pH 2) and incubated on ice for 5 min with the 
supernatant collected by centrifugation. Centrifugation speed was 1000 xg for 1 min at 4°C. 
Samples were re-suspended in loading buffer and subjected to western blotting.
Western blot analysis
Western blot analysis was performed on isolated brain capillaries from rats and plasma and 
whole blood lysates from rats and humans. Plasma and whole blood were processed as 
described previously6,18. Capillaries were isolated as described above and then lysed in 
buffer containing 1% NP-40, 150mM NaCl, 10mM Tris-HCl, 2mM EGTA, 50mM NaF, 1% 
phosphatase and 1% protease inhibitors. The lysate was centrifuged at 17,000 xg for 30 
minutes. The supernatant was used for Western blotting. Primary antibodies against amylin 
(1:2,000, T-4157, Bachem-Peninsula Laboratories, CA), occludin (1:300, 71-1500, 
Invitrogen, MA), claudin-5 (1:1,000, 35-2500, Invitrogen, MA), ZO-1 (1:300, 61-7300, 
Invitrogen, MA), collagen IV (1:1,000, ab6586, Abcam, MA), caveolin1 (1:1,000, sc-894, 
Santa Cruz) or β-actin (1:10,000, PIMA515739, Fisher, PA) were used in these analyses. 
Equal loading in Western blot experiments was verified by re-probing with a monoclonal 
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anti-β actin antibody (raised in mouse, clone BA3R, Thermo Scientific; 1:2000). Protein 
levels were compared by densitometric analysis using ImageJ software.
Real-Time Quantitative Reverse Transcription PCR
Expression levels of caveolin-1 and collagen IV in rat brain capillaries were measured using 
a protocol described previously29. Caveolin-1 primers (forward: 5′-
CTTAAATCACAGCCCAGGGAAAC-3′ and reverse: 5′-
GCGTCGTACACTTGCTTCTC-3′) and collagen IV primers (forward: 5′-
AAATGGCGCTCCTGATCCAA-3′ and reverse: 5′-TTCTTGTGGAGTTCTCGCCC-3′) 
were used in these experiments. Actin primers (forward: 5′-
CTGGCTCCTAGCACCATGAA-3′ and reverse: 5′-
AAAACGCAGCTCAGTAACAGTC-3′) were used as internal controls.
Cell culture and flow cytometry analysis
Prior to plating, culture flasks were coated with cell attachment factor solution (123-100, 
Sigma, MO). Brain microvascular endothelial cells from WT adult Sprague Dawley rats 
(RA-6023, Cell Biologics, Chicago, IL) were plated for 24 hours and used for experiment 
when they reached 70%–90% confluency. Cells were incubated with 50 μM human amylin 
(AS-60804, AnaSpec, CA) for 2 hours at 370C. Cells were dissociated with trypsin and 
washed with cold PBS before being stained with PI and Annexin V, according to 
manufacture protocol (V13241, Life Technologies, MA). Apoptotic cells and necrotic cells 
were detected with analytical flow cytometer (Becton-Dickinson LSRII).
Statistical analysis
Parametric comparison of two groups was done using two-tailed unpaired t-test. Non-
parametric comparison of two groups was done using Mann–Whitney unpaired t-test. Two-
ways analysis of variance with repeated measures followed by Bonferroni post-hoc tests 
were used to analyze the Morris water maze data. Data are presented as means + s.e.m. 
Difference between groups was considered significant when P < 0.05. All analyses were 
performed using GraphPad Prism 5.0 software.
Results
Impaired neurological functioning upon inducing amylin dyshomeostasis in rats
Both male and female HIP rats had increased plasma levels of amylin (Fig 1A) and 
developed overt hyperglycemia (>200 mg/dl; non-fasted; Fig 1B). Western blot analysis of 
amylin in plasma samples (Fig 1A) showed multiple molecular weight bands (higher amylin 
immunoreactive signal is seen in HIP rats compared to WT rats). The higher molecular 
weight bands could correspond to circulating amylin aggregates, as suggested by previously 
published data18,28,49, or amylin binding to plasma components (including plasma APOE; 
see below).
In contrast to WT littermate rats that had normal behavior, HIP rats had gait abnormalities 
and impaired balance (Supplementary movies) spontaneous forelimb use (Fig 1C), hind limb 
clasping (Fig 1D) and altered balance on a stationary inclined plane (Fig 1E). HIP rats and 
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WT controls had similar swim speeds (Fig 1F); however, latency to platform over the twenty 
learning trials was longer for HIP rats compared to WT littermates (Fig 1G; two-way 
ANOVA; P=0.03) indicating that HIP rats had impaired learning. Reference memory, 
defined as the latency to cross the platform at 24 hours after the second acquisition day 
(probe trial; Fig 1H), was similar for HIP and WT rats indicating no significant memory 
deficits associated with amylin dyshomeostasis once the task had been learned. Compared to 
males, female HIP rats developed hyperglycemia and neurologic deficits (Fig 1B and 
Supplementary movies) later in life (i.e., ~12 months vs. ~18 months of age). Balance and 
gait abnormalities were milder in females compared to male HIP rats.
Brain white matter injury in HIP rats
Based on in vivo magnetic resonance imaging (MRI; T2-weighted sequences), the brains of 
HIP rats had structural abnormalities (Fig 2A), which were not present in control WT 
littermates. Compared to controls, brains of diabetic male HIP rats showed areas of high T2 
signal in the lateral hippocampus and around the temporal horns of the lateral ventricles (Fig 
2A; arrows) and expansion of the ventricles (Fig 2B). Expansion of the ventricles and the 
high T2 signal in the surrounding tissue (Fig 2B) may reflect defects in the resorption of 
cerebrospinal fluid or/and subcortical atrophy. Because the current MRI protocol did only 
include coronal T2 images, we cannot formally distinguish between these possibilities.
The volume of brain parenchyma was smaller in diabetic animals compared to controls (Fig 
2C). Injured ependyma (arrow head; Fig 2D) and amylin deposition in choroid plexus (Fig 
2E) was found in HIP rats with considerably enlarged ventricles.
The brains of rats with falls and impaired balance often revealed intracerebral hemorrhages 
(arrow; Fig 2F), which were not found in control WT littermates.
We used the fluorescent microsphere technique to assess the brain perfusion status in 
diabetic HIP rats relative to controls. The retrieval of fluorescent microspheres was lower in 
brain capillaries (but not parenchymal tissue) of HIP rats compared to controls (Fig 2G) 
suggesting brain hypoperfusion in HIP rats.
Immunohistochemical analysis of brain paraffin sections (corpus callosum, lateral ventricle 
area, thalamus and hypothalamus) from diabetic rats showed parenchymal rarefaction. HIP 
rat brains had a loss of MBP immunoreactivity compared to brains from control animals (Fig 
3A). LFB stain of the white matter (Fig 3B) showed the same degree of myelin loss in the 
brains of diabetic rats compared to controls. Vacuoles were found through the entire white 
matter in HIP rats compared to controls.
Cerebral microhemorrhages and perivascular astrocyte recruitment in HIP rats
Histologic analysis of brain tissues from HIP rats showed microhemorrhages (Fig 4A; 
staining with Prussian blue dye). Serial staining of the periventricular region with the amylin 
antibody (Fig 4B) showed amylin deposits in microvessels (red arrows) and perivascular 
areas (inset; brown deposits). Vascular amylin deposition coincided with white matter 
vacuolation (arrow head). At higher magnification, the same brain area stained with 
hematoxylin and eosin (H&E) showed loss of cellular details and erythrocytes around a 
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blood vessel (Fig 4C). Amylin was present within the vessel wall (Fig 4D) and was 
associated with enlarged Virchow-Robin spaces. In contrast, tissue sections from similar 
levels of the brain from a WT animal had no vascular or tissue abnormalities. Staining for 
GFAP revealed robust recruitment of astrocytes in areas of vascular tissue damage (Fig 4E), 
whereas sections taken at a similar level of the hypothalamus from a control animal lacked 
obvious abnormalities, including no astrocytosis near intact microvessels. Amylin deposition 
was also found in association with infarction cores (as in Fig 4F) and disrupted vessel walls 
(Fig 4G,H). Amylin deposition was also present in hippocampal capillaries of HIP rats (Fig 
4I).
Cerebral microhemorrhages and perivascular astrocyte recruitment following intravenous 
infusion of aggregated amylin in AKO rats
HIP rats had elevated circulating levels of aggregated amylin (Fig 1A). To test whether 
circulating aggregated amylin injures the endothelium independently of glucotoxicity, we 
generated rats with deleted amylin gene (AKO rats; Fig 5A–D). AKO rats were 
intravenously infused with aggregated human amylin (2 μg/g body weight, q.d., 7 days; 
approximately three order of magnitude higher than the physiological level of amylin in HIP 
rats). Western blot analysis of blood lysates from amylin-infused AKO rats, HIP rats and 
human with type-2 diabetes showed similar distributions of amylin-positive molecular 
complexes (Fig 5E). Infusion of aggregated amylin provoked accumulation of amylin in the 
brain microvessels (Fig 5F), astrocyte recruitment in areas of vascular injury (Fig 5G) and 
brain microhemorrhages (Fig 5H); however, the white matter in amylin-injected animals was 
intact as assessed by in vivo MRI (Fig 5I).
Vascular amylin deposition is modulated by the amylin-APOE interaction
To test for a possible interaction of amylin with APOE in vivo, AKO rats (which express rat 
APOE, but lack amylin) were intravenously infused with combined aggregated human 
amylin (2 μg/g body weight) and APOE4 (1.2 μg/g body weight), or only aggregated human 
amylin for seven days (q.d.). Western blot analysis of plasma samples from rats in the two 
groups showed greater amylin binding to APOE4 compared to the endogenous rat APOE 
(Fig 6A), consistent with previous ex vivo data demonstrating that APOE4 modulates 
amylin aggregation22. To further test the interaction of amylin with plasma APOE, plasma 
samples from HIP rats were enriched in APOE by immunoprecipitation and were analyzed 
by Western blot with an anti-amylin antibody. Fig 6B depicts amylin that formed molecular 
complexes with plasma APOE in HIP rats. Not surprisingly, amylin bound to other plasma 
apolipoproteins as indicated by the immunoreactivity signal of amylin in APOA-I enriched 
by immunoprecipitation (Fig 6B)
Because amylin appears to bind to APOE4 (Fig 6A) in vivo, we hypothesized that infusion 
of APOE4 would exacerbate systemic amylin dyshomeostasis and cerebral vascular injury in 
HIP rats. To test this hypothesis, HIP rats were intravenously infused with APOE4 (1.2 μg/g 
body weight, q.d., for 7 days). The infusion of APOE4 enhanced amylin accumulation in the 
brains of HIP rats (Fig 6C,D). Fig 6D depicts leakage of amylin from a brain microvessel of 
a HIP rat that was infused with APOE4. No obvious extravasation of APOE4 was present in 
the APOE4-infused HIP rats.
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Shared feature of amylin vasculopathy in brains of HIP rats, human amylin-infused AKO 
rats and human with dementia and type-2 diabetes
Immunohistochemical analysis with an amylin antibody of brain tissues from patients with 
type-2 diabetes and dementia (T2D-De) showed vascular changes associated with amylin 
deposition. Fig 7A and B display sections from the brain of a 93 year old man (APOE 4/4 
carrier with type-2 diabetes and CERAD definite AD, Braak stage V and CAA severity 2). 
The vascular histopathology includes amylin deposits in the smooth muscle layer of 
arterioles (Fig 7A) and distortion of the amylin-positive vascular wall contours in capillaries 
(Fig 7B). Fig 7C shows a brain section from a 92 years old woman with type-2 diabetes and 
unknown APOE genotype (CERAD definite AD, Braak stage V and CAA severity 3). 
Amylin deposition was found in association with disruption of the vessel wall (Fig 7C). Fig 
7D is from the brain of another man (91 years old, APOE 3,4 carrier, CERAD definite AD, 
Braak stage V, but no CAA). Amylin immunoreactivity signal was detected in an area 
corresponding to a chronic infarct. In the brain that is displayed in Fig 7A, amylin is co-
localized with perivascular reactive astrocyte recruitment in disrupted blood vessel walls 
(Fig 7E). Reactive astrocytosis was lower around blood vessels of aged control individuals, 
with the caveat of the limited sample size. These pathologic changes were not present in the 
brain blood vessels of healthy aged individuals. Fig 7F provides a representative section 
from the 3 brains investigated in this study. Immunoconfocal microscopy analysis of amylin 
and collagen IV, a component of the basement membrane structure of the blood vessels, in 
the brain tissue from the 91 years old patient described above showed amylin deposition in 
an arteriole (arrow; Fig 7G) and a presumed capillary profile (head arrow; Fig 7G). Brain 
microvessels of HIP rats (Fig 7H) and AKO rats that were intravenously infused with 
aggregated human amylin (Fig 7I) had similar amylin deposits as in dementia patients who 
also had type-2 diabetes. In contrast, brain sections from a WT rat showed no amylin 
staining in brain blood vessels (Fig 7J).
Vascular amylin deposition injures endothelial cells and degrades tight junction 
components
To assess the impact of aggregated amylin on the endothelium, cerebral capillaries were 
isolated from HIP and WT rat brains and stained for amylin and caveolin-1, a protein that is 
abundant in endothelial cells. Areas of amylin deposition (green) showed weak 
immunoreactive caveolin signal (red; Fig 8A) suggesting the loss of endothelial cells. 
Consistent with immunoconfocal data, Western blot analysis demonstrated depletion of 
caveolin and collagen in brain capillary lysates from HIP rats compared to WT littermates 
(Fig 8B). There was similar depletion of collagen and caveolin-1 in human amylin-infused 
AKO rats (Fig 8B). The transcript levels for caveolin-1 and collagen IV were unchanged 
(Fig 8C) suggesting that the loss of capillary stability was associated with degradation of 
basement membrane structure and endothelium.
A flow cytometry analysis of cultured brain microvascular endothelial cells from rats was 
performed to test the viability of endothelial cells after exposure to aggregated human 
amylin. The interaction of aggregated human amylin with endothelial cells resulted in a 
significant increase of both early apoptotic (AnV+/PI−) and end-stage apoptotic (AnV+/PI+) 
populations, and a reduction of the live cell population (AnV−/PI−; Fig 8D).
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The tight junction components, claudin, occludin and ZO adapter proteins were degraded in 
cerebral capillaries from HIP rats (Fig 8E). There was some reduction in tight junction 
components in amylin-infused AKO rats (Fig 8E). Thus, microhemorrhages and amylin 
vasculopathy in HIP rat brains were associated with endothelial damage.
Discussion
Our data suggest that the amyloidogenicity of the human amylin peptide, amylin 
hypersecretion and plasma APOE are important mediators of amylin deposition in the 
cerebral microvasculature. Vascular amylin deposition was associated with endothelial cell 
damage and degradation of tight junctions that could explain the associated 
microhemorrhages and recruitment of perivascular astrocytes that occurred in HIP rats and 
in AKO rats infused with aggregated human amylin. Accumulated injury to cerebral small 
vessels can contribute to hypoperfusion leading to injury of brain parenchyma, loss of brain 
volume, and neurologic deficits (as seen in HIP rats; Fig 8F – proposed mechanism). Our 
findings are consistent with previous reports that implicated amylin dyshomeostasis as a 
contributor to the development of type-2 diabetes9,15,16,25–27 and cardiovascular 
disease17–19. The most important finding of this study is the demonstration of amylin-
provoked microhemorrhages in HIP rats and AKO rats infused with aggregated human 
amylin. This provides direct evidence that diabetes-associated amylin dyshomeostasis 
provokes a microangiopathy. This is a noteworthy finding because amylin deposits are 
present in the brain microvessels of patients with type-2 diabetes and dementia. Cerebral 
microhemorrhages occur frequently in patients with both ischemic and hemorrhagic stroke50 
and in individuals with cerebral amyloid angiopathy (CAA)4. Different from CAA, brain 
microvessels in AKO rats infused with aggregated human amylin showed concentric amylin 
deposition indicating that circulating aggregated amylin results in luminal amylin 
deposition. Thus, amylin-mediated narrowing of brain microvessels is a likely contributor to 
brain hypoperfusion and parenchymal loss leading to impaired neurological functioning in 
diabetic HIP rats. Cerebral microvascular injury that occurs in patients with type-2 diabetes 
is suggested to result from nonenzymatic glycation of proteins and subsequent production of 
toxic derivatives that induce endothelial cell oxidative damage32,33. The induction of 
cerebral microhemorrhages and surrounding neuropil injury occurred in amylin-infused 
AKO rats in the absence of hyperglycemia, which suggests that circulating aggregated 
amylin is a pathologic substrate for endothelial dysfunction in the setting of diabetes. 
Further study is required to establish a causal link between the level of circulating amylin 
and the effect of the resulting microvascular injury on brain parenchyma and functional 
outcomes in humans.
The cellular and molecular mechanisms that underlie the impact of cerebral microvascular 
injury on neural circuit function are complex and incompletely understood. This limitation 
stems in part from a paucity of experimental models51,52. In HIP rats, neurological deficits 
are associated with white matter injury caused by vascular amylin deposition. The present 
results indicate that expressing human amylin in species that do not develop type-2 diabetes 
(i.e. mice and rats) can provide a means to better understand the complex vascular factors 
affecting white matter integrity in patients with diabetes and dementia.
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APOE is a plasma protein that serves as a ligand for low density lipoprotein receptors, 
participates in the transport of cholesterol and other lipids among various cells of the body53 
and is present in amylin amyloid-containing pancreatic tissue from humans23,24. The 
infusion of APOE4 exacerbated amylin-mediated capillary injury and brain amylin 
accumulation in HIP rats. The result suggests an interaction between amylin and plasma 
APOE as a potential mechanism underlying brain amylin pathology. Because APOE4 may 
modulate amylin aggregation22, we speculate that elevated levels of plasma APOE4 could 
trigger the formation of toxic amylin aggregates in the blood. Additional studies are needed 
to elucidate the potential role of APOE alleles in promoting vascular amylin deposition.
Amylin plays a complex role in modulating the peripheral energy balance11–14. We 
demonstrated that systemic amylin dyshomeostasis contributes to the microvascular injury in 
the setting of diabetes. Thus, amylin dyshomeostasis may be a therapeutic target in diabetes-
associated stroke and dementia.
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Amylin, blood glucose and neurologic deficits in HIP rats. A. Western blot analysis of 
amylin in plasma from HIP and wild type (WT) male and female littermates, 15 months of 
age (M-male, F-female). B. Blood glucose in HIP and WT male and female littermates. C. 
Spontaneous forelimb use in male HIP rats vs. WT littermates assessed at 15 months of age 
by forepaws-to-wall contact time during vertical rearing up in the cylinder test (n = 5). D. 
Pathologic hind limb clasping in a 15 months old male HIP rat compared to a WT littermate 
rat. E. Inclined plane test in 15 months old male HIP rats vs. WT rat littermates (n = 5). F. 
Swim speed for HIP and WT rats in the Morris water maze test (n = 10, 15–16 months old). 
G. Latency for HIP and WT rats to swim to target platform in Morris water maze test (n = 
10, 15–16 months old rats). H. Latency to platform in the probe trial. Error bars represent 
mean ± SEM; **P < 0.01; ***P < 0.0001; by unpaired two-tailed Student’s t test (E,G,H–J), 
log-rank test (B,C).
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Periventricular injury and hypoperfusion in HIP rats. A. Three slices (1, 3 and 5 out of 7 
consecutive slices 1mm apart) of coronal T2-weighted MR images comparing the brains of a 
15 months old male HIP rat vs. a WT littermate rat. Hyperintensity areas (↑) in the lateral 
hippocampus and temporal horns of HIP rats reflect extracellular fluid accumulation. B,C. 
Volumes of ventricles and brain parenchyma in male HIP and WT littermate rats computed 
from coronal T2-weighted MR images; 1 image pixel area = 0.024 mm2 (n = 7). D. 
Hematoxylin and Eosin (H&E) staining of the lateral ventricle area in brains of HIP rats 
with considerably enlarged ventricles. E. Immunohistochemistry analysis with an amylin 
antibody of the choroid plexus in the same rat as in (D). F. Example of intracerebral 
hemorrhages (↑) that occured in male HIP rats, but not WT littermates (>12 months of age). 
G. Cerebral perfusion in male HIP and WT rats at ~15 months of age (n = 3) assessed by the 
retrieval from brain capillaries and parenchyma of intravenously infused fluorescent 
microspheres. Experiments were repeated three times for all representative images. Error 
bars represent mean ± SEM; *P < 0.05; **P < 0.01; n.s., not significant; by unpaired two-
tailed Student’s t test (B,C,F). Scale bar, 500 μm in D and 100 μm in E.
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White matter rarefaction in HIP rats. A. Representative immunohistochemical (IHC) 
analysis of myelin basic protein (MBP) in the hypothalamus (htha) of a 15 months old male 
HIP rat vs. a WT littermate rat. Analysis (graph) of MBP level in HIP and WT brain white 
matter areas (cc- corpus callosum; lv- lateral ventricle area; tha- thalamus; htha- 
hypothalamus) (n = 3). B. Representative IHC analysis of myelin level assessed by Luxol 
fast blue (LFB) staining in the hypothalamus (htha) of a 15 months old male HIP rat vs. a 
WT littermate rat. Analysis was carried out in the same brain areas as in above (n = 3). C. 
Scoring criteria for demyelination in myelin binding protein and Luxol fast blue staining. 
Exampled images of Luxol fast blue staining of HIP rat brain tissues. Experiments were 
repeated three times for all representative images. Error bars represent mean ± SEM; *P < 
0.05; **P < 0.01; n.s., not significant; by Mann-Whitney unpaired two-tailed t test. Scale 
bar, 100 μm.
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Brain microhemorrhages and perivascular astrocyte recruitment in HIP rats.
A. Analysis of the number of brain microhemorrhages stained with Prussian blue dye in HIP 
vs. WT rats (n = 7). Representative staining with Prussian blue dye of a microhemorrhage in 
the lateral hypothalamus-ventricular area of a 15 months old HIP rat. Same brain area from a 
WT rat is the control. B. Representative image of serial staining with an amylin antibody in 
the same brain region as in (A) shows amylin deposits in microvessels (↑) and perivascular 
area (inset; brown deposits) in HIP rats but not WT rats. White matter vacuolation (▲) was 
found in HIP rat brains. C. Images with a higher magnification (40× and 100×, respectively) 
of the same brain area stained with H&E D. Representative IHC analysis of amylin in a 
small arteriole (HIP vs. WT rats). E. Representative IHC analysis of activated astrocytes in 
areas of vascular injury in the brain of a HIP rat assessed by staining for glial fibrillary 
acidic protein (GFAP, brown). Images are from hypothalamus. Same area from a WT rat 
brain is the control. F–H. IHC analysis of amylin in areas of microvascular injury in HIP rat 
brains. I. Representative IHC analysis of vascular amylin deposition in the hippocampus of a 
HIP rat. Error bars represent mean ± SEM; *P < 0.05; by unpaired two-tailed Student’s t test 
(A). Experiments are repeated three times for all representative images. Scale bar, 100 μm in 
A,B,F; 50 μm in C (top) E,G,H; 20 μm in D and 10 μm in C (lower panel) and I.
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Infusion of aggregated amylin in amylin knockout (AKO) rats. A. Amylin gene deletion 
with CRISPR/CAS9. The two cut guide sites are shown below in bold. Preproamylin 















B. Gel electrophoresis showing a ~ 1.2 kb from the WT rat amylin DNA and a ~ 430 bp 
sequence remaining after deletion of amylin gene. C. Gel electrophoresis showing a 650 bp 
sequence that includes part of the amylin gene that was deleted in transgenic animals. D. 
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Western blot analysis of pancreatic tissues demonstrating that the protein level of amylin is 
reduced in the AKO rats compared to WT littermates. E. Cropped Western blot of amylin in 
blood lysates from amylin-infused AKO rats, HIP rats and type-2 diabetes (T2D) patients. 
Amylin band at ~10 kDa (the amylin dimer) required longer exposure time and is displayed 
separately. Experiments are repeated twice. F,G. Representative images of IHC staining with 
amylin (F) and co-staining for amylin (brown) and GFAP (green) (G) in the cerebral cortex 
of an amylin-infused AKO rat vs. an age-matched AKO rat without amylin infusion (n = 3). 
H. Prussian blue dye in the brain cortex area of an amylin-infused AKO rat vs. an age-
matched AKO rat without amylin infusion. Analysis of the number of brain 
microhemorrhages in amylin-infused AKO and control AKO rats (n = 6). I. Three slices (1, 
3 and 5 out of 7 consecutive slices 1mm apart) of coronal T2-weighted MR images 
comparing the brain in an AKO rat before and after infusion with aggregated human amylin 
(2 μg/g body weight, q.d., 7 days) (n = 3).
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Amylin interaction with plasma apolipoproteins in vivo. A. Cropped Western blot of amylin 
in plasma from AKO rats infused with amylin alone or in combination with APOE4 (n = 3). 
B. Western blot analysis with an anti-amylin antibody of HIP rat plasma samples that were 
enriched in APOE or APOA-1 by immunoprecipitation. (n = 3). C. Representative 
immunofluorescence images of amylin-APOE4 vascular deposition in brain microvessels of 
HIP rats injected with human APOE4. Analysis of amylin fluorescence intensity in the brain 
blood vessels of WT, HIP and APOE4-infused HIP rats (graph; n = 3). D. Same as in C for 
brain parenchyma. The bar graph shows analysis of amylin fluorescence intensity in brain 
parenchyma of WT, HIP and APOE4-infused HIP rats (n = 3). Error bars represent mean ± 
SEM; *P < 0.05. **P < 0.01, ***P < 0.0001; by unpaired two-tailed Student’s t test. Scale 
bars, 50 μm in B–D; 20 μm in G and H.
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Cerebral amylin vasculopathy in patients with dementia and type-2 diabetes (T2D-De), HIP 
rats and amylin-infused AKO rats. A–D. Representative IHC analysis of amylin deposition 
(brown) in the brain blood vessels of T2D-De patients (n = 3 patients). E. Representative 
IHC showing co-staining of GFAP (green) and amylin (brown) in areas of cerebral vascular 
injury on brain sections from the same T2D-De patients as in A–D. F. Representative IHC 
analysis with amylin and GFAP antibodies on brain sections from healthy aged individuals 
(Ctl; n = 3). G. Representative immunofluorescence images of amylin deposition (green) on 
the luminal side of the vessel basement membrane stained with Collagen IV (red) in the 
brain microvessels of T2D-De patients (n = 3). H–J. Representative immunofluorescence 
images of amylin deposition (green) on the luminal side of vessel basement membrane 
stained with Collagen IV (red) in the brain microvessels of HIP rats (H; n = 3), amylin-
infused AKO rats (i; n = 3) and age-matched WT rat brains (J; n = 3). Experiments are 
repeated twice for all representative images. Scale bars, 10 μm in A,B; 20 μm in G–J; 50 μm 
in D–F and 100 μm in C.
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Vascular amylin deposition injures endothelial cells and degrades tight junction components. 
A. Representative immunofluorescence images of isolated brain capillaries from HIP and 
WT littermate rats (15 months old) showing endothelial cells (caveolin1, red) and amylin 
deposition (green) (n = 3 rats). Scale bar, 10 μm. Experiments are repeated twice for all 
representative images and results. B. Cropped Western blot of caveolin-1 (Cav1) and 
collagen IV (Col IV) in capillary lysates from HIP and WT rats (n = 5; left panel), and 
amylin-infused AKO and control AKO (no amylin) rats (n = 3; right panel). Corresponding 
densitometry analyses of caveolin1 and collagen IV levels are displayed in the lower panel. 
C. Quantitative real-time PCR of caveolin1 and collagen IV mRNA in isolated capillaries 
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from HIP and WT rats (caveolin1, n = 4; collagen IV, n = 3). D. Flow cytometry analysis of 
rat brain microvascular endothelial cells apoptosis when incubated with 50 μM human 
amylin (n = 3). Apoptotic cells are detected with Annexin V (AnV) and dead cells are 
detected with Propidium Iodide (PI). Live cells are AnV−/PI−, early apoptotic cells are AnV
+/PI−, end-stage apoptotic cells are AnV+/PI+, necrotic cells are AnV−/PI+. E. Cropped 
Western blot of endothelial cell tight junction proteins (ZO-1, occludin, and claudin-5) in 
capillary lysates from HIP and WT brain (n = 5; left panel), and amylin-infused AKO and 
control AKO rats (n = 3; right panel). F. Proposed mechanism: aggregated amylin causes 
endothelial dysfunction and microvascular injury and is modulated by amylin transport in 
the brain via plasma APOE. Corresponding densitometry analyses of tight junction protein 
levels are displayed in the lower panel. Error bars represent mean ± SEM; *P < 0.05, **P < 
0.01, ***P < 0.001, n.s., not significant; by unpaired two-tailed Student’s t test 
(B,C,D,E,F,G).
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